SGLT2 inhibitors get another safety warning
Three pharmaceutical companies have called on health professionals to check signs of ketoacidosis in patients taking SGLT2 inhibitors.
Prescribers should inform patients of signs and symptoms of metabolic acidosis when first prescribing SLGT2 inhibitors and advise them to seek urgent medical attention should they arise. These signs include nausea, abdominal pain, excessive thirst and unusual fatigue, according to a signed letter from AstraZeneca, Janssen and Boehringer Ingelheim sent directly to health professionals.
Patients should also be tested for ketones when presenting with acidosis